IND-enabling activities advancing for PSMA-targeting ADC. (PRNewswire) - Nov 10, 2025 - "IND-enabling activities are ongoing for the Company's exatecan-based, prostate-specific membrane antigen (PSMA)-targeting ADC with completion of these activities expected by the end of 2025."
Preclinical • Oncology
|